WntResearch recently announced that the Spanish authorities have approved the revised study plan for the phase II study NeoFox with the drug candidate Foxy-5 in colon cancer. The company has introduced new endpoints on the primary tumour already at the patients' surgery, which enables significantly earlier data readout and thus cost and time savings.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.29 SEK | -3.04% |
|
+6.47% | +77.07% |
Jun. 20 | WntResearch Presents Ad H Holes Observations from the NeoFox Study at ESMO GI | CI |
May. 03 | WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+77.07% | 13.8M | |
+20.95% | 127B | |
+23.00% | 116B | |
+25.15% | 27.69B | |
-19.75% | 19.62B | |
-16.57% | 16.26B | |
-16.56% | 15.49B | |
+11.19% | 14.81B | |
-46.65% | 14.39B | |
+57.74% | 14.11B |
- Stock Market
- Equities
- WNT Stock
- News WntResearch AB
- WntResearch AB Announces New Study Plan Approves for Wnt Research's Phase II Study